Effectiveness of switching from dipeptidyl peptidase‐4 inhibitor to oral glucagon‐like peptide‐1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching

Glycated haemoglobin levels decreased from 7.5% to 7.0% after 6 months of switching from DPP-4 inhibitors to oral semaglutide.

• Body mass index reduced from 29.7 kg/m² to 28.8 kg/m² over the same period.
• Significant improvements were noted particularly in participants with poor glycaemic control.
• In a matched analysis, the switching group exhibited better glycaemic control and weight management compared to the DPP-4 inhibitor group.
• The findings suggest that transitioning to oral semaglutide may be more beneficial for glycaemic and weight control in obese individuals with type 2 diabetes.

AI simplified